Article
ICPE 2023 Featured Presentations from Analysis Group Consultants
Analysis Group presented a symposium, podium presentation, and six research posters at the 39th annual International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) in Halifax, Nova Scotia.
Chief Epidemiologist and Managing Principal Mei Sheng Duh and Vice President Marianne Cunnington presented a symposium titled “Bias Introduced by COVID-19 Related Healthcare Disruptions in Safety and Effectiveness Studies: Proposing Methodological Solutions,” during which they described a new method that they developed to adjust for bias introduced by COVID-19-associated health care disruptions in RWE studies. Dr. Duh and Dr. Cunnington were joined by speakers from GSK, the London School of Hygiene & Tropical Medicine, and the European Medicines Agency.
Additionally, Dr. Duh participated in the podium presentation of “Likelihood of Antimicrobial Resistance in Urinary E. coli Isolates Comparing Female Patients with Recurrent Versus Non-recurrent Uncomplicated Urinary Tract Infection in the United States.” This study was coauthored by Analysis Group consultants and researchers from GSK and Hackensack University Medical Center.
Further details on the symposium, podium presentation, and posters are available in our ICPE 2023 Presentation Guide.
During the conference, Dr. Cunnington, who was elected to ISPE’s Board, took office as the representative for industry and service providers in Europe and Africa. Analysis Group is proud to have supported this conference as a gold sponsor.
Meet Our People
Marianne Cunnington
Vice PresidentDr. Cunnington has over 20 years of experience as a pharmaceutical industry epidemiologist. She specializes in the generation of real-world evidence (RWE) in support of the development and life cycle management of pharmaceutical and vaccine products, with a particular focus on regulatory risk management strategies and product benefit-risk assessments. Dr. Cunnington’s research expertise includes the design, negotiation, and execution of real-world components of risk management plans for new product submission to regulators in the US, UK, EU, Japan, and South Korea, including studies of post-approval safety in the EU; post-marketing requirements and commitments in the US; and pregnancy registries. Prior to joining Analysis Group, she served in several senior epidemiology positions at pharmaceutical companies, including as the chair of GSK’s peer review forum for all pharmaceutical RWE projects; as a member of GSK’s Global Safety Board; as head of epidemiology at Novartis Vaccines; and as a managing board member of Innovative Medicines’ public-private partnership initiative to build an integrated European real-world data (RWD) network to monitor medication safety in pregnancy.